{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017860","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.777262+00:00","generated_at":"2026-06-15T22:49:13.384550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MindMed Q1 net loss $24.8M, cash $129.4M; key trial readouts on track for late 2023","bullets":["Net loss of $24.8M in Q1 2023 vs $18.5M in Q1 2022; R&D expenses rose to $12.6M (up $2.4M YoY).","Cash and equivalents $129.4M at Mar 31, 2023; expected to fund operations into H1 2025.","Phase 2b MM-120 for GAD and Phase 2a for ADHD both on track for topline results in late 2023.","Appointed Mark R. Sullivan as Chief Legal Officer in April 2023.","Plan to initiate Phase 1 trial of MM-402 for ASD in 2023; pre-clinical data at ASCP May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017860","json":"https://secwatch.observer/filing/0000950170-23-017860.json","markdown":"https://secwatch.observer/filing/0000950170-23-017860.md","text":"https://secwatch.observer/filing/0000950170-23-017860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/0000950170-23-017860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/mnmd-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:49:13.384550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebb283c222eb3dc3d7308057460a9bfd457d43f5","claim":"Definium Therapeutics, Inc. updated its the quarter ended March 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/0000950170-23-017860-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}